Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?
An overview of the application of markers for solid tumours is presented. Some of the potential problems with general cancer tests are considered as well as the ways in which the more specific markers have been applied. The limited specificities of markers defined so far remain a serious limitation but they have found useful clinical application. Their use in radioimmunolocalisation provides an interesting challenge to the physical methods of tumour localisation and the possibilities of drug targeting by antibodies are as exciting as the difficulties are formidable. It is, I suggest, a field that will continue to evolve and be productive.
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000032:analysis; D006801:Humans; D007116:Immunization, Passive; D007158:Immunologic Techniques; D008722:Methods; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis* / Q000276:immunology; D011379:Prognosis; D011863:Radioimmunoassay; D000509:alpha-Fetoproteins / Q000032:analysis
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins